A BRAF mutation is present in up to 15% of patients with mCRC3,7

Colorectal cancer is the second-most-deadly cancer in the United States—estimated to cause more than 50,000 deaths in 20188
  • Approximately 21% of colorectal cancer patients have metastatic disease at diagnosis9

mCRC, metastatic colorectal cancer.

THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

BRAF mutations are detected almost exclusively in patients with RAS wild-type mCRC7,10-12

BRAF mutations are detected almost exclusively in patients with RAS wild-type CRC. BRAF V600 mutations are the most common BRAF mutations. Fewer than half of patients with CRC have wild-type RAS or BRAF.
BRAF mutations are detected almost exclusively in patients with RAS wild-type mCRC
BRAF V600 mutations are the most common BRAF mutations
Fewer than half of patients with mCRC have wild-type RAS or BRAF
BRAF mutations are detected almost exclusively in patients with RAS wild-type mCRC
BRAF V600 mutations are the most common BRAF mutations
Fewer than half of patients with mCRC have wild-type RAS or BRAF

mCRC, metastatic colorectal cancer.


Patients with BRAF-mutant mCRC have a poor prognosis and there are presently no FDA-approved therapies specifically indicated for these patients5,6,10,11

Outcomes in patients with BRAF-mutant mCRC are generally poor in later lines of therapy using products currently approved for mCRC patients2-4
overall survival (OS) is 4 to 6 months
progression-free survival (PFS) is 2-3 months
overall response rate (ORR) is 4% to 8%

mCRC, metastatic colorectal cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.


Testing at diagnosis can determine whether your patient has a RAS or BRAF mutation5,6

Discover the power in knowing
References:
1. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE. 2012;7(10):e47054. 2. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101(4):715-721. 3. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753-762. 4. Clinicaltrials.gov. US National Library of Medicine. S1406 phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF mutant metastatic colorectal cancer. https://clinicaltrials.gov/ct2/show/results/NCT02164916. Accessed December 14, 2018. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.4.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed December 19, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V.3.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed December 19, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 7. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227-235. 8. National Cancer Institute. SEER cancer stat facts: colorectal cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed November 1, 2018. 9. Zadlo, J. Cost-effectiveness of new and emerging treatment options for the treatment of metastatic colorectal cancer. Am J Manag Care. 2018;24(suppl 7):S118-S124. 10. Ursem C, Atreya CE, Van Loon K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer. 2018;8:13-23. 11. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422. 12. Dinu D, Dobre M, Panaitescu E, et al. Prognostic significance of KRAS gene mutations in colorectal cancer—preliminary study. J Med Life. 2014;7(4):581-587. 13. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623-4632.